Immunomodulatory effects of HUC-MSCs therapy: enhancing adaptive and innate immune responses in aging frailty
-
By
-
Ce Huang
-
Yingqian Zhu
-
Xue Gong
-
Shengyu Feng
-
Guangying Huo
-
Hailiang Liu
-
Hua Jiang
-
Zhongmin Liu
-
July 13, 2026
Clinical Scorecard: Therapeutic Role of HUC-MSCs in Modulating Immune Responses: Boosting Adaptive and Innate Immunity in Aging-Related Frailty
At a Glance
| Category | Detail |
|---|
| Condition | Aging-related frailty |
| Key Mechanisms | Immunomodulation through HUC-MSCs affecting immune cell dynamics and inflammation |
| Target Population | Frail elderly individuals aged 60-80 years |
| Care Setting | Clinical trial setting |
Key Highlights
- HUC-MSCs induce a time-dependent recalibration of the immune system in frail elderly patients.
- Significant reductions in B cell hyperactivity and enhanced NK cell cytotoxicity were observed post-therapy.
- Immunomodulatory changes correlated with clinical improvements in grip strength and gait speed.
Guideline-Based Recommendations
Diagnosis
- Frailty diagnosed according to Fried’s phenotypic criteria.
Management
- Intravenous infusion of HUC-MSCs at a dose of 1 × 10^6 cells/Kg.
Monitoring & Follow-up
- Assess immune cell dynamics and clinical performance metrics post-therapy.
Risks
- Exclusion criteria include severe cardiovascular comorbidities, advanced organ dysfunction, and cognitive impairment.
Patient & Prescribing Data
Frail adults aged 60-80 years with a life expectancy exceeding 12 months.
HUC-MSC therapy is linked to improved physical performance and reduced pro-inflammatory cytokines.
Clinical Best Practices
- Utilize scRNA-seq for high-resolution profiling of immune responses.
- Monitor for changes in immune cell subsets associated with therapeutic response.
Related Resources & Content
